Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson Down Over 4% After Seeking Drug Approval -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 12:38pm EDT

Johnson & Johnson (JNJ) is currently at $134.01, down $6.10 or 4.35%

-- Would be lowest close since June 4, 2019, when it closed at $133.73

-- On pace for largest percent decrease since Dec. 14, 2018, when it fell 10.04%

-- Earlier Friday, The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) said it submitted an application with the U.S. Food and Drug Administration seeking approval of its new subcutaneous formulation of Darzalex, or daratumumab, for certain patients with multiple myeloma

-- Credit Suisse initiated Johnson & Johnson at outperform with a price target of $156.00/share, Benzinga reported

-- Currently down three consecutive days; down 5.23% over this period

-- Worst three day stretch since the three days ending May 29, 2019, when it fell 6.05%

-- Down 3.78% month-to-date

-- Up 3.84% year-to-date

-- Down 9.54% from its all-time closing high of $148.14 on Jan. 22, 2018

-- Up 6.42% from 52 weeks ago (July 13, 2018), when it closed at $125.93

-- Down 9.35% from its 52 week closing high of $147.84 on Dec. 13, 2018

-- Up 9.09% from its 52 week closing low of $122.84 on Dec. 24, 2018

-- Traded as low as $132.97; lowest intraday level since June 4, 2019, when it hit $132.58

-- Down 5.1% at today's intraday low; largest intraday percent decrease since May 29, 2019, when it fell as much as 6.24%

-- Worst performer in the DJIA today

-- Second worst performer in the S&P 500 today

-- Subtracted 41.36 points from the DJIA so far today

All data as of 12:12:23 PM

Source: Dow Jones Market Data, FactSet

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -0.11% 26787.36 Delayed Quote.14.83%
JOHNSON & JOHNSON -0.46% 130.72 Delayed Quote.1.77%
NASDAQ 100 -0.02% 7842.333734 Delayed Quote.22.28%
NASDAQ COMP. -0.10% 8048.649481 Delayed Quote.19.83%
S&P 500 -0.14% 2966.15 Delayed Quote.18.32%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07:39aMARKET SNAPSHOT: Stock Futures Edge Higher As Banks Kick Off Earnings Season
DJ
07:24aJOHNSON & JOHNSON : Raises Outlook, Beats Profit Estimates
DJ
06:56aJOHNSON & JOHNSON : Strong 3Q for Johnson & Johnson and a better outlook
AQ
06:45aJOHNSON & JOHNSON : Reports 2019 Third-Quarter Results
PR
02:48aJ&J's Courtroom Losses Pile Up -- WSJ
DJ
10/14Business events scheduled for Tuesday
AQ
10/14J&J'S JANSSEN : FDA OK's Xarelto in Acutely Ill Medical Patients
DJ
10/14Johnson & Johnson's Legal Challenges Mount
DJ
10/10JOHNSON & JOHNSON : Must Halve Price of Lifesaving TB Drug Bedaquiline
AQ
10/09MARKET SNAPSHOT: Stocks Close Higher, End Two-day Skid As China-U.S. Trade Ta..
DJ
More news
Financials (USD)
Sales 2019 81 582 M
EBIT 2019 25 367 M
Net income 2019 18 056 M
Debt 2019 8 650 M
Yield 2019 2,89%
P/E ratio 2019 19,5x
P/E ratio 2020 17,6x
EV / Sales2019 4,33x
EV / Sales2020 4,05x
Capitalization 345 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 149,05  $
Last Close Price 130,72  $
Spread / Highest target 29,3%
Spread / Average Target 14,0%
Spread / Lowest Target -5,14%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.77%344 992
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287
NOVO NORDISK AS17.25%121 422